Patents Represented by Attorney Robert L. Niblack
  • Patent number: 4272626
    Abstract: A method of producing 1-epi-2-deoxyfortimicin A, key intermediates therefor and an improved process for synthesizing the key intermediate 1,2-di-epi-fortimicin A.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: June 9, 1981
    Assignee: Abbott Laboratories
    Inventors: Ronald E. Carney, James B. McAlpine
  • Patent number: 4272528
    Abstract: Certain phosphonoacetyl aminoacids have been found to be useful antiviral agents suitable to combat herpes virus infection of various types.
    Type: Grant
    Filed: August 14, 1980
    Date of Patent: June 9, 1981
    Assignee: Abbott Laboratories
    Inventors: Anne M. Von Esch, Alford M. Thomas, John S. Fairgrieve, John H. Seely
  • Patent number: 4269970
    Abstract: A 1,2-carbamate of fortimicin B and derivatives represented by the formula: ##STR1## wherein: R is hydrogen or monocyclicaryloxycarbonyl, R.sub.1 is hydrogen or monocyclicaryloxycarbonyl; and R.sub.2 is selected from the group consisting of loweralkyl, loweralkoxycarbonyl aminoloweralkyl, hydroxyloweralkyl, hydroxy-substituted aminolowerakyl, an amino acid residue, and N-protected amino acid residue, or when R and R.sub.1 are hydrogen, R.sub.2 can also be hydrogen; and the acid addition salts thereof when R,R.sub.1 or R.sub.2 are hydrogen or an unprotected aminoacid residue.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: May 26, 1981
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Jerry R. Martin
  • Patent number: 4269858
    Abstract: 2-Fluoronorepinephrine has been found to have antihypertensive activity when orally administered to warm-blooded animals.
    Type: Grant
    Filed: April 28, 1980
    Date of Patent: May 26, 1981
    Assignee: Abbott Laboratories
    Inventors: John F. DeBernardis, John J. Kyncl
  • Patent number: 4268691
    Abstract: By condensation of anisoyl chloride with 2,3-dichloroanisole under proper conditions, 2,3-dichloro-4-(hydroxybenzoyl)phenol is obtained directly.
    Type: Grant
    Filed: August 9, 1979
    Date of Patent: May 19, 1981
    Assignee: Abbott Laboratories
    Inventors: Anthony K. L. Fung, Donald E. Morrison, Andre G. Pernet
  • Patent number: 4264765
    Abstract: Highly water-soluble erythromycin A derivatives wherein the desosamine moiety is quaternized with an acyloxy-, benzoyloxy- or alkoxycarbonyl-(or carboxy)-acylmethyl iodide, bromine or chloride and esterified in the 2-position with loweralkyl or --(CH.sub.2).sub.n CO.sub.2 R", wherein R" is H, loweralkyl or substituted loweralkyl and n is an integer from 1-5. These new esters readily convert to erythromycin A upon administration to warm-blooded animals.
    Type: Grant
    Filed: February 20, 1980
    Date of Patent: April 28, 1981
    Assignee: Abbott Laboratories
    Inventors: Nicholas S. Bodor, Leslie A. Freiberg
  • Patent number: 4264590
    Abstract: It has been found that dipeptides containing a 3-halo-D-alanine C-terminus are powerful antibacterials and produce a highly useful synergistic effect with antibiotics.
    Type: Grant
    Filed: June 9, 1980
    Date of Patent: April 28, 1981
    Assignee: Abbott Laboratories
    Inventors: Daniel I. Chu, Jerry R. Martin, Alford M. Thomas, Norman E. Wideburg
  • Patent number: 4263429
    Abstract: A fortimicin intermediate selected from the group consisting of 1,2',6'-tri-N-benzyloxycarbonylfortimicin B-4,5-carbamate and 1,2',6'-tri-N-acetylfortimicin A-4,5-carbamate. The compounds are useful as intermediates in the preparation of 2-epi-fortimicin B.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: April 21, 1981
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Jerry R. Martin
  • Patent number: 4262157
    Abstract: Decarboxylation of carboxylic acids using diazabicycloalkenes and, if desired, also a simple copper salt, as the means for decarboxylation.
    Type: Grant
    Filed: March 27, 1980
    Date of Patent: April 14, 1981
    Assignee: Abbott Laboratories
    Inventors: Yuji Hori, Yoshiaki Nagano, Hiroshi Taniguchi
  • Patent number: 4258712
    Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The equipment sets of this invention have a primary tube valve controlled by pilot liquid diverted from the secondary liquid flow path.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: March 31, 1981
    Assignee: Abbott Laboratories
    Inventors: Jack L. Harms, Joseph N. Genese, Andrew J. Muetterties
  • Patent number: 4256104
    Abstract: Gravitational flow system and equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: March 17, 1981
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Muetterties, Joseph N. Genese
  • Patent number: 4256105
    Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention have a tube of reduced diameter to restrict the flow of primary liquid to a predetermined rate.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: March 17, 1981
    Assignee: Abbott Laboratories
    Inventors: John J. Leahey, Andrew J. Muetterties, Joseph N. Genese
  • Patent number: 4255528
    Abstract: The use of catalytic amounts of tris(3-dimethylaminopropyl)amine promotes the formation of urethane linkages. Its unusual activity and properties make this compound very useful in the manufacture of rigid polyurethanes.
    Type: Grant
    Filed: September 24, 1979
    Date of Patent: March 10, 1981
    Assignee: Abbott Laboratories
    Inventors: Daniel S. Raden, Chala V. Maripuri, Frank C. Becker
  • Patent number: 4254116
    Abstract: 5H-[1]Benzopyrano[3,4-d]pyridines represented by the formula ##STR1## wherein each R.sub.1 is loweralkyl, R.sub.2 is alkyl, cycloalkyl or ##STR2## wherein Y is a straight or branched chain alkylene group having from 1 to 10 carbon atoms and each R.sub.4, R.sub.5 and R.sub.6 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl; and R.sub.3 is hydroxy, acyloxy, loweralkoxy, loweralkenyloxy, loweralkynyloxy or ##STR3## X is a straight or branched chain alkylene group having from one to eight carbon atoms, and wherein R.sub.7 and R.sub.8 are the same or different members of the group consisting of hydrogen or loweralkyl, or ##STR4## wherein X is a straight or branched chain alkylene group having from one to eight carbon atoms, a is an integer from 1 to 4, b is an integer from 1 to 4, Z is CH.sub.2, O, S or NR.sub.10 with R.sub.10 being hydrogen or loweralkyl, with the limitation that when Z is O or S, the sum of a and b is 3 or 4; and when Z is NR.sub.
    Type: Grant
    Filed: April 8, 1974
    Date of Patent: March 3, 1981
    Assignee: Abbott Laboratories
    Inventor: Cheuk M. Lee
  • Patent number: 4252972
    Abstract: 2',6'-Di-N-benzyloxycarbonylfortimicin B-1,2:4,5-bis-carbamate and fortimicin B-1,2:4,5-bis-carbamate and its salt are provided by the present invention. The compound is represented by the formula ##STR1## wherein each R is either hydrogen or benzyloxycarbonyl The bis-carbamate is useful as in intermediate in the preparation of fortamine bis-carbamate, which in turn is useful as an intermediate in the preparation of aminoglycoside antibiotics via glycosidation with suitably protected sugar moieties.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: February 24, 1981
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Jerry R. Martin
  • Patent number: 4252116
    Abstract: Equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention employ a novel flexible diaphragm valve as the air barrier.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: February 24, 1981
    Assignee: Abbott Laboratories
    Inventors: Joseph N. Genese, Andrew J. Muetterties
  • Patent number: 4250879
    Abstract: Gravitational flow system and equipment sets for the sequential administration of medical liquids wherein a primary liquid can be administered at a flow rate independent of the flow rate of a secondary liquid, and including a barrier substantially impervious to air to prevent the inadvertent administration of air when the secondary liquid is depleted. The sets of this invention employ a combined air barrier and liquid sequencing valve.
    Type: Grant
    Filed: February 28, 1979
    Date of Patent: February 17, 1981
    Assignee: Abbott Laboratories
    Inventor: Andrew J. Muetterties
  • Patent number: 4251532
    Abstract: An improved anti-hypertensive agent, the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine dihydrate.
    Type: Grant
    Filed: September 24, 1979
    Date of Patent: February 17, 1981
    Assignee: Abbott Laboratories
    Inventor: Robert Roteman
  • Patent number: 4251516
    Abstract: The present invention provides 2-deoxy-3-O-demethyl-fortimcins A and B and the 4-N-acyl and alkyl derivatives thereof, represented by the formula: ##STR1## wherein R is selected from the group consisting of hydrogen, acyl, aminoacyl,diaminoacyl,N-monoloweralkylaminoalkyl,N,N-diloweralkylaminoalky l, hydroxy-substituted aminoacyl,loweralkyl, aminoloweralkyl, N-monoloweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl and hydroxy-substituted aminoloweralkyl and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: February 17, 1981
    Assignee: Abbott Laboratories
    Inventors: Jerry R. Martin, John S. Tadanier, Paulette Johnson
  • Patent number: 4250304
    Abstract: Disclosed are 2-deoxy-2-substituted fortimicin A and B derivatives represented by the formula ##STR1## wherein R is hydrogen glycyl, .beta.-alanyl, acetyl, or .beta.-amino lower alkyl, R.sub.1 is hydrogen, amino, azido, halo, glycylamido, .beta.-alanyl amido or 2-O-methanesulfonyl and R.sub.2 is hydrogen or halo and their pharmaceutically acceptable salts. The compounds are active antibacterial agents.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: February 10, 1981
    Assignee: Abbott Laboratories
    Inventors: Jerry R. Martin, John S. Tadanier, Paulette Johnson, Alex M. Nadzan